Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells

C. Gaetano, I. Manni, G. Bossi, G. Piaggio, S. Soddu, A. Farina, L. J. Helman, A. Sacchi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We report the first evidence that differential transcriptional regulation of human chromogranin A (CHGA) gene expression occurs during in vitro treatment of tumorigenic neuroblastoma (NB) cells with retinoic acid (5 pM) and/or dibutyryl-cAMP (1 mM). The CHGA gene encodes a tissue specific protein restricted to cells of the diffuse neuroendocrine system, but also widely expressed among NB tumours. We previously reported that CHGA as well as other neuroendocrine markers are modulated during NB differentiation in vitro. To investigate, at the molecular level, the mechanisms leading to NB tumour cell differentiation during the treatment with biologically active compounds, we sequenced and functionally characterised 2169 bp of a genomic DNA clone encompassing the 5′ flanking region of the human CHGA gene. Computer-assisted analysis of the sequence revealed the presence of a cAMP responsive element at positions -56 to -49, and Sp1 binding sites at positions -181 to -176 and -216 to -210. Two novel 9 bp motifs, located at position -462 to -454 and -91 to -83 of the CHGA promoter were identified in the regulatory regions of two other neuroendocrine genes encoding for tyrosine hydroxylase and neuropeptide Y. In addition, in the first 1000 bp of the untranslated 5′ region, we found the presence of several putative DNA binding sites of bHLH molecules, a protein family regulating tissue specific differentiation. Transient transfection experiments of chloramphenicol acetyltransferase (CAT) deletion constructs, showed the presence of an active promoter within the first 455 bp upstream from the start site. This region conferred tissue specific expression to a CAT reporter gene. In addition, the transcriptional activity of this fragment was modulated during the induction of differentiation of NB cells treated by retinoic acid and/or dibutyryl-cAMP. These observations provide preliminary data regarding CHGA transcriptional regulation in NB cells, and indicate that retinoic acid and cAMP activate distinct, apparently competitive, transcriptional pathways during NB cell differentiation. The molecular characterisation of the mechanisms regulating CHGA expression in tumour and normal neuroendocrine tissue could lead to the identification of novel molecules potentially relevant for future gene therapy of NB tumours.

Original languageEnglish
Pages (from-to)447-452
Number of pages6
JournalEuropean Journal of Cancer
Volume31
Issue number4
DOIs
Publication statusPublished - 1995

Fingerprint

Chromogranins
Tretinoin
Neuroblastoma
Cell Differentiation
Chromogranin A
Chloramphenicol O-Acetyltransferase
Binding Sites
Genes
Neoplasms
Neurosecretory Systems
Neuroendocrine Tumors
5' Flanking Region
Nucleic Acid Regulatory Sequences
5' Untranslated Regions
Neuropeptide Y
DNA
Tyrosine 3-Monooxygenase
Reporter Genes
Genetic Therapy
Transfection

Keywords

  • chromaffin
  • chromogranin
  • differentiation
  • e-box
  • neuroblastoma
  • neuroendocrine
  • promoter

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells. / Gaetano, C.; Manni, I.; Bossi, G.; Piaggio, G.; Soddu, S.; Farina, A.; Helman, L. J.; Sacchi, A.

In: European Journal of Cancer, Vol. 31, No. 4, 1995, p. 447-452.

Research output: Contribution to journalArticle

Gaetano, C. ; Manni, I. ; Bossi, G. ; Piaggio, G. ; Soddu, S. ; Farina, A. ; Helman, L. J. ; Sacchi, A. / Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells. In: European Journal of Cancer. 1995 ; Vol. 31, No. 4. pp. 447-452.
@article{62a959e8688e40b492220d013ad0d541,
title = "Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells",
abstract = "We report the first evidence that differential transcriptional regulation of human chromogranin A (CHGA) gene expression occurs during in vitro treatment of tumorigenic neuroblastoma (NB) cells with retinoic acid (5 pM) and/or dibutyryl-cAMP (1 mM). The CHGA gene encodes a tissue specific protein restricted to cells of the diffuse neuroendocrine system, but also widely expressed among NB tumours. We previously reported that CHGA as well as other neuroendocrine markers are modulated during NB differentiation in vitro. To investigate, at the molecular level, the mechanisms leading to NB tumour cell differentiation during the treatment with biologically active compounds, we sequenced and functionally characterised 2169 bp of a genomic DNA clone encompassing the 5′ flanking region of the human CHGA gene. Computer-assisted analysis of the sequence revealed the presence of a cAMP responsive element at positions -56 to -49, and Sp1 binding sites at positions -181 to -176 and -216 to -210. Two novel 9 bp motifs, located at position -462 to -454 and -91 to -83 of the CHGA promoter were identified in the regulatory regions of two other neuroendocrine genes encoding for tyrosine hydroxylase and neuropeptide Y. In addition, in the first 1000 bp of the untranslated 5′ region, we found the presence of several putative DNA binding sites of bHLH molecules, a protein family regulating tissue specific differentiation. Transient transfection experiments of chloramphenicol acetyltransferase (CAT) deletion constructs, showed the presence of an active promoter within the first 455 bp upstream from the start site. This region conferred tissue specific expression to a CAT reporter gene. In addition, the transcriptional activity of this fragment was modulated during the induction of differentiation of NB cells treated by retinoic acid and/or dibutyryl-cAMP. These observations provide preliminary data regarding CHGA transcriptional regulation in NB cells, and indicate that retinoic acid and cAMP activate distinct, apparently competitive, transcriptional pathways during NB cell differentiation. The molecular characterisation of the mechanisms regulating CHGA expression in tumour and normal neuroendocrine tissue could lead to the identification of novel molecules potentially relevant for future gene therapy of NB tumours.",
keywords = "chromaffin, chromogranin, differentiation, e-box, neuroblastoma, neuroendocrine, promoter",
author = "C. Gaetano and I. Manni and G. Bossi and G. Piaggio and S. Soddu and A. Farina and Helman, {L. J.} and A. Sacchi",
year = "1995",
doi = "10.1016/0959-8049(95)00038-K",
language = "English",
volume = "31",
pages = "447--452",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Retinoic acid and camp differentially regulate human chromogranin a promoter activity during differentiation of neuroblastoma cells

AU - Gaetano, C.

AU - Manni, I.

AU - Bossi, G.

AU - Piaggio, G.

AU - Soddu, S.

AU - Farina, A.

AU - Helman, L. J.

AU - Sacchi, A.

PY - 1995

Y1 - 1995

N2 - We report the first evidence that differential transcriptional regulation of human chromogranin A (CHGA) gene expression occurs during in vitro treatment of tumorigenic neuroblastoma (NB) cells with retinoic acid (5 pM) and/or dibutyryl-cAMP (1 mM). The CHGA gene encodes a tissue specific protein restricted to cells of the diffuse neuroendocrine system, but also widely expressed among NB tumours. We previously reported that CHGA as well as other neuroendocrine markers are modulated during NB differentiation in vitro. To investigate, at the molecular level, the mechanisms leading to NB tumour cell differentiation during the treatment with biologically active compounds, we sequenced and functionally characterised 2169 bp of a genomic DNA clone encompassing the 5′ flanking region of the human CHGA gene. Computer-assisted analysis of the sequence revealed the presence of a cAMP responsive element at positions -56 to -49, and Sp1 binding sites at positions -181 to -176 and -216 to -210. Two novel 9 bp motifs, located at position -462 to -454 and -91 to -83 of the CHGA promoter were identified in the regulatory regions of two other neuroendocrine genes encoding for tyrosine hydroxylase and neuropeptide Y. In addition, in the first 1000 bp of the untranslated 5′ region, we found the presence of several putative DNA binding sites of bHLH molecules, a protein family regulating tissue specific differentiation. Transient transfection experiments of chloramphenicol acetyltransferase (CAT) deletion constructs, showed the presence of an active promoter within the first 455 bp upstream from the start site. This region conferred tissue specific expression to a CAT reporter gene. In addition, the transcriptional activity of this fragment was modulated during the induction of differentiation of NB cells treated by retinoic acid and/or dibutyryl-cAMP. These observations provide preliminary data regarding CHGA transcriptional regulation in NB cells, and indicate that retinoic acid and cAMP activate distinct, apparently competitive, transcriptional pathways during NB cell differentiation. The molecular characterisation of the mechanisms regulating CHGA expression in tumour and normal neuroendocrine tissue could lead to the identification of novel molecules potentially relevant for future gene therapy of NB tumours.

AB - We report the first evidence that differential transcriptional regulation of human chromogranin A (CHGA) gene expression occurs during in vitro treatment of tumorigenic neuroblastoma (NB) cells with retinoic acid (5 pM) and/or dibutyryl-cAMP (1 mM). The CHGA gene encodes a tissue specific protein restricted to cells of the diffuse neuroendocrine system, but also widely expressed among NB tumours. We previously reported that CHGA as well as other neuroendocrine markers are modulated during NB differentiation in vitro. To investigate, at the molecular level, the mechanisms leading to NB tumour cell differentiation during the treatment with biologically active compounds, we sequenced and functionally characterised 2169 bp of a genomic DNA clone encompassing the 5′ flanking region of the human CHGA gene. Computer-assisted analysis of the sequence revealed the presence of a cAMP responsive element at positions -56 to -49, and Sp1 binding sites at positions -181 to -176 and -216 to -210. Two novel 9 bp motifs, located at position -462 to -454 and -91 to -83 of the CHGA promoter were identified in the regulatory regions of two other neuroendocrine genes encoding for tyrosine hydroxylase and neuropeptide Y. In addition, in the first 1000 bp of the untranslated 5′ region, we found the presence of several putative DNA binding sites of bHLH molecules, a protein family regulating tissue specific differentiation. Transient transfection experiments of chloramphenicol acetyltransferase (CAT) deletion constructs, showed the presence of an active promoter within the first 455 bp upstream from the start site. This region conferred tissue specific expression to a CAT reporter gene. In addition, the transcriptional activity of this fragment was modulated during the induction of differentiation of NB cells treated by retinoic acid and/or dibutyryl-cAMP. These observations provide preliminary data regarding CHGA transcriptional regulation in NB cells, and indicate that retinoic acid and cAMP activate distinct, apparently competitive, transcriptional pathways during NB cell differentiation. The molecular characterisation of the mechanisms regulating CHGA expression in tumour and normal neuroendocrine tissue could lead to the identification of novel molecules potentially relevant for future gene therapy of NB tumours.

KW - chromaffin

KW - chromogranin

KW - differentiation

KW - e-box

KW - neuroblastoma

KW - neuroendocrine

KW - promoter

UR - http://www.scopus.com/inward/record.url?scp=0029035156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029035156&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(95)00038-K

DO - 10.1016/0959-8049(95)00038-K

M3 - Article

VL - 31

SP - 447

EP - 452

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -